Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Marc R Gastonguay"'
Publikováno v:
PLoS ONE, Vol 17, Iss 4, p e0247286 (2022)
Rare disease clinical trials are constrained to small sample sizes and may lack placebo-control, leading to challenges in drug development. This paper proposes a Bayesian model-based framework for early go/no-go decision making in rare disease drug d
Externí odkaz:
https://doaj.org/article/0abb8457e9e84dfda4ac392345ed3d5a
Publikováno v:
Neuropsychiatric Disease and Treatment, Vol 2011, Iss default, Pp 117-125 (2011)
Yan Feng1, Marc R Gastonguay2, Bruce G Pollock3,5, Ellen Frank3, Gail H Kepple4, Robert R Bies5,6,71Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb, Lawrenceville, NJ, USA; 2Metrum Institute, Tariffville, CT, USA; 3Department of Ps
Externí odkaz:
https://doaj.org/article/acc8cec367a14cd2becf4efe96dd6b3d
Autor:
Laura E. Schanberg, Lily (Yeruk) Mulugeta, Bolanle Akinlade, Hermine I. Brunner, Jianmeng Chen, Robert A. Colbert, Vincent Delgaizo, Marc R. Gastonguay, Rachel Glaser, Lisa Imundo, Daniel J. Lovell, Jocelyn H. Leu, Nael M. Mostafa, Robert M. Nelson, Peter A. Nigrovic, Nikolay P. Nikolov, Lisa G. Rider, Rebecca Rothwell, Chandrahas Sahajwalla, Renu Singh, Vikram Sinha, Carolyn L. Yancey, Lynne Yao
Publikováno v:
Arthritis & Rheumatology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::42ccce1811effae897137b13f08f7027
https://doi.org/10.1002/art.42534
https://doi.org/10.1002/art.42534
Autor:
Gagan Kushal, Nicole R. Zane, Ana Ruiz-Garcia, Marc R. Gastonguay, Rena Eudy-Byrne, Susan C. Adeniyi-Jones, Walter K. Kraft
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2171-2183 (2021)
Clinical and Translational Science
Clinical and Translational Science
Results from Blinded Buprenorphine OR Neonatal morphine solution (BBORN), a previous phase III trial in infants with neonatal opioid withdrawal syndrome (NOWS), demonstrated that sublingual buprenorphine resulted in a shorter duration of treatment an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb3ab162305ebe0bd20c01d0cbb5bf95
https://doi.org/10.1111/cts.13074
https://doi.org/10.1111/cts.13074
Autor:
Kevin J. Downes, Austyn Grim, Laura Shanley, Ronald C. Rubenstein, Athena F. Zuppa, Marc R. Gastonguay
Publikováno v:
Antimicrob Agents Chemother
Extended interval dosing of tobramycin is recommended for treatment of pulmonary exacerbations in adults and older children with cystic fibrosis (CF), but data are limited in patients less than 5 years of age. We performed a retrospective population
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6a79267af479b5d98a1790f9756f6e6
https://doi.org/10.1128/aac.02377-21
https://doi.org/10.1128/aac.02377-21
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 47:91-104
Duchenne muscular dystrophy (DMD) is a rare X-linked genetic pediatric disease characterized by a lack of functional dystrophin production in the body, resulting in muscle deterioration. Lower body muscle weakness progresses to non-ambulation typical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::689e539a60871322ecf51d07e8aae02b
https://doi.org/10.1007/s10928-020-09671-7
https://doi.org/10.1007/s10928-020-09671-7
Autor:
Kevin J Downes, Austyn Grim, Laura Shanley, Ronald C Rubenstein, Athena F Zuppa, Marc R. Gastonguay
BackgroundExtended interval dosing (EID) of tobramycin is recommended for treatment of pulmonary exacerbations in adults and older children with cystic fibrosis (CF), but data are limited in patients less than 5 years of age.MethodsWe performed a ret
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74917435521e96a0ae1d0711daff4acc
https://doi.org/10.1101/2022.01.02.22268643
https://doi.org/10.1101/2022.01.02.22268643
Autor:
Athena F, Zuppa, Nicole R, Zane, Ganesh, Moorthy, Heidi J, Dalton, Alan, Abraham, Ron W, Reeder, Joseph A, Carcillo, Andrew R, Yates, Kathleen L, Meert, Robert A, Berg, Anil, Sapru, Peter, Mourani, Daniel A, Notterman, J Michael, Dean, Marc R, Gastonguay
Publikováno v:
Pediatric Critical Care Medicine. 20:62-70
Limited data exist on the effects of extracorporeal membrane oxygenation on pharmacokinetics of cefepime in critically ill pediatric patients. The objective was to describe cefepime disposition in children treated with extracorporeal membrane oxygena
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4cff362939e0dd156715f87073611f2
https://doi.org/10.1097/pcc.0000000000001786
https://doi.org/10.1097/pcc.0000000000001786
Autor:
Morris Barocas, Maria Rosario, Nathanael L. Dirks, Marc R. Gastonguay, Mark T. Osterman, Jayson D. Wilbur, Karen Lasch
Publikováno v:
Alimentary Pharmacology & Therapeutics
Background Prospectively designed studies assessing the exposure-response profile of vedolizumab are lacking. Observational exposure-response data for vedolizumab are limited and have not been adjusted for potential confounding factors, particularly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1866775e7289531c88e12b9169e4fee
http://europepmc.org/articles/PMC6590294
http://europepmc.org/articles/PMC6590294
Publikováno v:
PLOS ONE. 17:e0247286
Rare disease clinical trials are constrained to small sample sizes and may lack placebo-control, leading to challenges in drug development. This paper proposes a Bayesian model-based framework for early go/no-go decision making in rare disease drug d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1c6fb40390e728cb86cb86f72759d8b
https://doi.org/10.1371/journal.pone.0247286
https://doi.org/10.1371/journal.pone.0247286